Alunbrig (brigatinib) — Cigna
Inflammatory Myofibroblastic Tumor
Initial criteria
- Patient age ≥ 18 years
- Patient has anaplastic lymphoma kinase (ALK)-positive disease
- Patient has advanced, recurrent, or metastatic disease OR the tumor is inoperable
Approval duration
1 year